Treatment of invasive pulmonary aspergillosis according to recommendations of Infectious Diseases Society of Americaриведена в соответствии со стандартной системой, используемой в руководствах IDSA.

G. A. Klyaksova; Клясова Г. А.; A. A Maschan; Масчан А. А.; A. V. Veselov; Веселов А. В.

doi:10.17650/1818-8346-2008-0-1-2-47-57

Treatment of invasive pulmonary aspergillosis according to recommendations of Infectious Diseases Society of Americaриведена в соответствии со стандартной системой, используемой в руководствах IDSA.

Authors: Klyaksova G.A.¹, Maschan A.A², Veselov A.V.³
Affiliations:
1. Research Center for Hematology of Russian Academy of Medical Sciences
2. Federal State Enterprise «Federal Research Clinical Center of Pediatric Hematology, Oncology and Immunology of Russian Public Health
3. Research Institute of antimicrobial chemotherapy
Issue: No 1-2 (2008)
Pages: 47-57
Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
Published: 23.05.2008
URL: https://oncohematology.abvpress.ru/ongm/article/view/690
DOI: https://doi.org/10.17650/1818-8346-2008-0-1-2-47-57
ID: 690

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Some recommendations of Infectious Diseases Society of America for diagnosis and treatment of invasive aspergillosis with lung involvement, which is the most frequent clinical manifestation of aspergillar infection.
Full version of recommendations was published in one of the editions of journal “Clinical microbiology and antibacterial chemotherapy” (2008. Т. 10. №2). Fungi of Aspergillus kin is the main etiologic cause of life-threatening infections in immunocompromised patients, such as patients with prolonged neutropenia, advanced stages of HIV infection, hereditary immunodeficiency states and after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and/or lung transplantation. This version of recommendations for treatment of invasive aspergillosis from IDSA (Infectious Diseases Society of America) substituted the former recommendations published in 2000. The level of evidence of treatment data is given in according with standard scheme used in the IDSA guidance.